Abstract
Reductase activity of 17beta-hydroxysteroid oxidoreductase in biopsy specimens of prostatic cancer and benign hyperplasia, and prostatic intraepithelial neoplasia and serum concentrations of testosterone, 5alpha-dihydrotestosterone, 4-androstene-3,17-dione were compared in patients and healthy individuals. Reductase activities of 17beta-hydroxysteroid oxidoreductase in soluble fraction of prostatic biopsy specimens decreased in the following order: prostatic cancer>prostatic intraepithelial neoplasia>>benign prostatic hyperplasia. No differences in serum concentrations of testosterone, 5alpha-dihydrotestosterone, 4-androstene-3,17-dione between these three groups of patients were found, while the mean serum concentration of these androgens in patients with prostatic tumors did not surpass the threshold normal values for men. Hence, high reductase activity of 17beta-hydroxysteroid oxidoreductase can be associated with pathogenetic mechanisms of human malignant prostatic tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
